Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de seguridad y eficacia que evalúa CTX001 en sujetos con enfermedad de células falciformes grave

21 de agosto de 2026 actualizado por: Vertex Pharmaceuticals Incorporated

Un estudio de fase 1/2/3 para evaluar la seguridad y eficacia de una dosis única de células madre y progenitoras hematopoyéticas humanas CD34+ modificadas con CRISPR-Cas9 autólogas (CTX001) en sujetos con enfermedad de células falciformes grave

Este es un estudio de Fase 1/2/3 de dosis única, de etiqueta abierta, multisitio y de un solo brazo en sujetos con enfermedad de células falciformes (ECF) grave. El estudio evaluará la seguridad y la eficacia de las células madre y progenitoras hematopoyéticas humanas CD34+ modificadas con CRISPR-Cas9 autólogas (hHSPC) utilizando CTX001.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

63

Fase

  • Fase 2
  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Düsseldorf, Alemania
        • University Hospital Duesseldorf
      • Regensburg, Alemania
        • Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine, Paediatric Haemotology, Oncology and Stem Cell Transplantation
      • Brussels, Bélgica
        • Hopital Universitaire des Enfants Reine Fabiola (HUDERF)
      • Toronto, Canadá
        • The Hospital for Sick Children
    • California
      • Palo Alto, California, Estados Unidos, 94304
        • Lucile Packard Children's Hospital of Stanford University
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Ann & Robert Lurie Children's Hospital of Chicago
      • Chicago, Illinois, Estados Unidos, 60612
        • University of Illinois at Chicago Hospitals and Health Systems
    • New York
      • New York, New York, Estados Unidos, 10032
        • Columbia University Medical Center (21+ years)
      • New York, New York, Estados Unidos, 10032
        • Columbia University Medical Center (≤21 years)
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Children's Hospital of Philadelphia
    • Tennessee
      • Memphis, Tennessee, Estados Unidos, 38105
        • St. Jude Children's Research Hospital
      • Nashville, Tennessee, Estados Unidos, 37203
        • The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers
    • Texas
      • San Antonio, Texas, Estados Unidos, 78229
        • Methodist Children's Hospital/Texas Transplant Institute
      • Paris, Francia
        • Hôpital Necker Enfants malades
      • Rome, Italia
        • Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS
      • London, Reino Unido
        • Imperial College Healthcare NHS Trust, Hammersmith Hospital
      • London, Reino Unido
        • Royal London and St Bartholomew's Hospital, Pathology and Pharmacy Building

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

12 años a 35 años (Niño, Adulto)

Acepta Voluntarios Saludables

No

Descripción

Criterios clave de inclusión:

  • Diagnóstico de enfermedad de células falciformes grave según lo definido por:
  • Genotipo de enfermedad de células falciformes grave documentado
  • Historial de al menos dos eventos graves de crisis vasooclusiva por año durante los dos años anteriores a la inscripción
  • Elegible para trasplante autólogo de células madre según el criterio de los investigadores

Criterios clave de exclusión:

  • Un donante emparentado compatible con antígeno leucocitario humano (HLA) 10/10 disponible
  • Trasplante previo de células madre hematopoyéticas (TPH)
  • Infección bacteriana, viral, fúngica o parasitaria clínicamente significativa y activa

Pueden aplicarse otros criterios de inclusión/exclusión definidos en el protocolo

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Exa-cel
Exa-cel (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants received a single infusion of exa-cel through a central venous catheter on Day 1.
Administered by IV infusion following myeloablative conditioning with busulfan.
Otros nombres:
  • Exagamglogene autotemcel
  • CTX001

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants Who Have Not Experienced Any Severe Vaso-occlusive Crisis (VOC) for at Least 12 Consecutive Months (VF12) After Exa-cel Infusion
Periodo de tiempo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
A VOC is a condition of SCD characterized by vaso-occlusion presenting as recurrent pain episodes. The percentage of participants who remain VOC free after achieving VF12 were data reported in the outcome measure.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants Who Achieve Neutrophil Engraftment
Periodo de tiempo: Up to 24 months post exa-cel infusion.
Neutrophil engraftment is defined as the first day of 3 consecutive measurements of absolute neutrophil count (ANC)≥500/μL on 3 different days, within 42 days after exa-cel infusion without the use of unmodified CD34+ cells after reaching the nadir, defined as ANC <500/µL.
Up to 24 months post exa-cel infusion.
Time to Neutrophil Engraftment for Participants Who Achieve Neutrophil Engraftment
Periodo de tiempo: Up to 24 months post exa-cel infusion.
Neutrophil engraftment is defined as the first day of 3 consecutive measurements of absolute neutrophil count (ANC)≥500/μL on 3 different days, without use of the unmodified CD34+ cells after reaching the nadir, defined as ANC<500/μL. Time to neutrophil engraftment was calculated by the neutrophil engraftment date subtract exa-cel infusion date +1.
Up to 24 months post exa-cel infusion.
Time to Platelet Engraftment for Participants Who Achieve Platelet Engraftment
Periodo de tiempo: From Exa-cel infusion up to 2 years after exa-cel infusion
Platelet engraftment is defined as the first day of 3 consecutive measurements of unsupported (no platelet transfusions for the last 7 days) platelet ≥50,000/μL on 3 different days after Exa-cel infusion. For participants discharged early day 7 after the last platelet transfusion will be the day of platelet engraftment, as long as 3 subsequent and consecutive unsupported measurements on 3 different days are >50,000/μL. For participants who have been discharged prior to platelet engraftment, it is recommended to collect blood every 2 to 3 days to obtain an accurate assessment of platelet engraftment. Time to platelet engraftment was defined as first of 3 consecutive measurements on 3 different days with platelet ≥50 × 109/L without a platelet transfusion for 7 consecutive days.
From Exa-cel infusion up to 2 years after exa-cel infusion
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Periodo de tiempo: From receiving exa-cel infusion up to 2 years
From receiving exa-cel infusion up to 2 years
Transplant-related Mortality (TRM) Within 100 Days After Exa-cel Infusion
Periodo de tiempo: Within 100 days after exa-cel infusion
The transplant-related mortality is defined as death related to Busulfan and/or exa-cel infusion. The number and proportion of TRM participants who have died within 100 days, or with at least 100 days post exa-cel infusion.
Within 100 days after exa-cel infusion
Transplant-related Mortality Within 12 Months Post Exa-cel Infusion
Periodo de tiempo: Within 12 months post exa-cel infusion
The transplant-related mortality is defined as death related to Busulfan and/or exa-cel infusion. The number and proportion of TRM within 12 months will be summarized for participants who have died within 12 months, or with at least 12 months post exa-cel infusion.
Within 12 months post exa-cel infusion
All-cause Mortality
Periodo de tiempo: From exa-cel infusion up to 2 years
All-cause mortality from exa-cel infusion up to 2 years
From exa-cel infusion up to 2 years

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants Free From Inpatient Hospitalization for Severe VOCs Sustained for at Least 12 Months (HF12)
Periodo de tiempo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Periodo de tiempo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The VF12 defines absence of any severe vaso-occlusive crises (VOCs) for at least 12 consecutive months after exa-cel infusion. Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs were included in the analysis. Relative reduction from baseline was calculated as 100 % × (Baseline value - post-baseline value) / Baseline value. Annualized rate is calculated by the Total number of events/number of years.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With at Least 90% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Periodo de tiempo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of participants with at least 90% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With at Least 80% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Periodo de tiempo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of participants with at least 80% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With at Least 75% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Periodo de tiempo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of participants with at least 75% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With at Least 50% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Periodo de tiempo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of participants with at least 50% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Duration of Severe VOC Free in Participant Who Have Achieved VF12
Periodo de tiempo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The VF12 means the absence of any severe VOC for at least 12 consecutive months after exa-cel infusion. The evaluation of the severe VOC free duration in participants who achieved VF12 started 60 days after the last RBC transfusion for post transplant support or SCD management.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Relative Reduction From Baseline in Annualized Rate of Inpatient Hospitalizations for Severe VOCs Up to 24 Months After Exa-cel Infusion
Periodo de tiempo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion. Relative reduction from baseline is calculated as 100% × (Baseline value - post-baseline value) / Baseline value. Annualized rate is calculated by the Total number of events/number of years.

Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs are included in the analysis.

From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Relative Reduction From Baseline in Annualized Duration of Hospitalization for Severe VOCs Who Did Not Achieve HF12 Up to 24 Months After Exa-cel Infusion
Periodo de tiempo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion. Relative reduction from baseline is calculated as 100% × (Baseline value - post-baseline value) / Baseline value. Annualized rate is calculated by the Total number of events/number of years.

Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs are included in the analysis.

From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With Sustained Fetal Hemoglobin (HbF) Greater Than or Equal to (≥) 20% for at Least 3 Months
Periodo de tiempo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management. The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With Sustained HbF ≥ 20% for at Least 6 Months
Periodo de tiempo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management. The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With Sustained HbF ≥20% for at Least 12 Months
Periodo de tiempo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management. The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Number of Annualized Red Blood Cells (RBC) Units Transfused After Exa-cel Infusion
Periodo de tiempo: 2 years after exa-cel infusion
The evaluation of the number of annualized RBC units transfused after exa-cel infusion started 12 months after exa-cel infusion.
2 years after exa-cel infusion
Participants With Relative Reduction From Baseline in Number of Annualized Units of Red Blood Cells Transfused
Periodo de tiempo: 2 years after exa-cel infusion
Relative reduction from baseline = 100% × (Baseline value - post baseline value)/Baseline value. The evaluation of the number of annualized RBC units transfused after exa-cel infusion started 12 months after exa-cel infusion.
2 years after exa-cel infusion
Total Fetal Hemoglobin (HbF) Concentration Over Time
Periodo de tiempo: 2 years after exa-cel infusion
2 years after exa-cel infusion
Total Hemoglobin (Hb) Concentration Over Time
Periodo de tiempo: 2 years after exa-cel infusion
2 years after exa-cel infusion
Change From Baseline in Reticulocyte Count Over Time
Periodo de tiempo: 2 years after exa-cel infusion
2 years after exa-cel infusion
Change From Baseline in Indirect Bilirubin Over Time
Periodo de tiempo: 2 years after exa-cel infusion
2 years after exa-cel infusion
Percentage of Participants With Detectable Haptoglobin Over Time
Periodo de tiempo: 2 years after exa-cel infusion
2 years after exa-cel infusion
Percentage of Participants With Lactate Dehydrogenase (LDH) Level <300 Units Per Liter (U/L) Over Time
Periodo de tiempo: 2 years after exa-cel infusion
2 years after exa-cel infusion
Percentage of Alleles With Intended Genetic Modification Present in Peripheral Blood Leukocytes Over Time
Periodo de tiempo: 2 years after exa-cel infusion
2 years after exa-cel infusion
Percentage of Alleles With Intended Genetic Modification Present in CD34+ Cells of Bone Marrow Over Time
Periodo de tiempo: 2 years after exa-cel infusion
2 years after exa-cel infusion
Change in Patient-reported Outcome (PRO) Over Time Assessed Using on a 11-point Numerical Rating Scale [NRS]) for Participants ≥12 and <18 Years of Age
Periodo de tiempo: 2 years after exa-cel infusion
The 11-point pain numerical rating scale (NRS) is used to measures pain intensity on a 1-dimensional score ranging from 0 (no pain) to 10 (worst possible pain).
2 years after exa-cel infusion
Change in Patient-reported Outcome (PRO) Over Time Assessed Using on a 11-point Numerical Rating Scale [NRS]) for Participants ≥18 and ≤35 Years of Age
Periodo de tiempo: 2 years after exa-cel infusion
The 11 point pain numerical rating scale (NRS) is used to measures pain intensity on a 1 dimensional score ranging from 0 (no pain) to 10 (worst possible pain).
2 years after exa-cel infusion
Change in PRO Over Time Assessed Using EuroQol Quality of Life Scale (EQ-5D-Y)Visual Analogue Scale (VAS) for Participants ≥12 and <18 Years of Age
Periodo de tiempo: 2 years after exa-cel infusion
The EQ-5D VAS is a version of the EQ-5D designed for children and adolescents S). The EQ VAS records the subject's self-rated health on a 100-point VAS scale that ranged from 0 (worst imaginable health) to 100 (best imaginable health) points.
2 years after exa-cel infusion
Change in PRO Over Time Assessed Using EuroQol Quality of Life Scale (EQ-5D-5L) for Participants ≥18 and ≤35 Years of Age
Periodo de tiempo: 2 years after exa-cel infusion
The EQ-5D VAS is a version of the EQ-5D designed for children and adolescents S). The EQ VAS records the subject's self-rated health on a 100-point VAS scale that ranged from 0 (worst imaginable health) to 100 (best imaginable health) points.
2 years after exa-cel infusion
Change in PRO Over Time Assessed Using Functional Assessment of Cancer Therapy-bone Marrow Transplant (FACT-BMT) Score for Participants ≥18 and ≤35 Years of Age
Periodo de tiempo: 2 years after exa-cel infusion
The Functional Assessment of Cancer Therapy-Bone Marrow Transplant scale (FACT-BMT) is a quality of life instrument that assesses the effects of bone marrow transplantation (BMT) on a patient's physical, social/family, emotional, and functional well-being while taking into consideration BMT-specific concerns. The assessment has different questions, each scored on a Likert scale from 0-4. The overall score is computed by adding scores of the questions and falls in the range 0-148, with higher scores indicating higher levels of overall well-being.
2 years after exa-cel infusion
Change in PRO Over Time Assessed Using Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) Score on Different Domains for Participants ≥18 and ≤35 Years of Age
Periodo de tiempo: 2 years after exa-cel infusion
ASCQ-Me is a disease-specific HRQoL questionnaire for adults with sickle cell disease that assesses Emotional Impact, Pain Impact, Social Functioning Impact, Stiffness Impact, Sleep Impact, Pain Episode Frequency, and Pain Episode Severity. Domain scores are reported as T-scores standardized to a reference population where mean = 50, and SD = 10. A change of approximately 5 points (1/2 SD) is considered clinically meaningful. An increase of 5 points indicates improvement for the impact domains, whereas a decrease of 5 points indicates improvement for the Pain Episode Frequency and Pain Episode Severity domains. For impact domain items higher score indicates better HRQoL and lower disease burden. For Pain items lower score indicates a better outcome. Scores are interpreted relative to the reference population mean of 50, taking into account the direction of scoring for each domain.
2 years after exa-cel infusion
Change in PRO Over Time Assessed Using Pediatric Quality of Life Inventory (PedsQL) for Participants Greater Than or Equal to (≥) 12 and Less Than (<) 18 Years of Age
Periodo de tiempo: 2 years after Exa-cel infusion
PedsQL scores were used to assess quality of life of participants. It is a standardized, generic instrument for measuring health related quality of life (HRQoL) in children and adolescents. It includes different domains (Psychosocial health, physical functioning, emotional functioning, social functioning, and school functioning). When completing the PedsQL questionnaires, respondents were asked to provide a response on a 5-point scale ranging from 0 (never a problem) to 4 (almost always a problem). Responses were then transformed to a 0 to 100 score, with higher scores reflecting better quality of life.
2 years after Exa-cel infusion
Change in PRO Over Time Assessed Using Pediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease Module (SCD) for Participants Greater Than or Equal to (≥) 12 and Less Than (<) 18 Years of Age
Periodo de tiempo: 2 years after exa-cel infusion
The PedsQL Sickle Cell Disease Module (PedsQL SCD) is a disease-specific module of the PedsQL. The tool measures self-reported health-related quality of life in participants with SCD across 9 domains: pain and hurt, pain impact, pain management (mgmt), worry I, worry II, emotions, treatment, communication I, and communication II. When completing the PedsQL SCD Module questionnaires, respondents were asked to provide a response on a 5-point scale ranging from 0 (never a problem) to 4 (almost always a problem). Responses were then transformed to a 0 to 100 score, with higher scores reflecting better quality of life.
2 years after exa-cel infusion

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

27 de noviembre de 2018

Finalización primaria (Actual)

7 de julio de 2025

Finalización del estudio (Actual)

7 de julio de 2025

Fechas de registro del estudio

Enviado por primera vez

9 de noviembre de 2018

Primero enviado que cumplió con los criterios de control de calidad

15 de noviembre de 2018

Publicado por primera vez (Actual)

19 de noviembre de 2018

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

21 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir